> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regeneron Revenue Climbs 36% To $5.1 Billion As Sanofi Profit Share Surges, Plus A $1 Billion Up-Front Deal
- URL: https://www.bullished.co/regeneron-revenue-climbs-36-to-5-1-billion-as-sanofi-profit-share-surges-plus-a-1-billion-146e9a04/
- Published: 2026-10-30T11:07:35.000Z
- Updated: 2026-10-30T11:07:35.000Z
- Description: Sanofi collaboration revenue rose 68% in the third quarter, and Regeneron raised its 2026 research spending range while cutting its SG&A range.
- Author: Matteo Parrino
- Tags: Earnings, REGN, Industry: Healthcare

[Regeneron](https://www.bullished.co/tag/regn/), the biotech behind Eylea HD, Libtayo and Praluent, said third-quarter [revenue rose 36% to $5.1 billion](https://www.sec.gov/Archives/edgar/data/0000872589/000087258926000032/exhibit991q32026.htm?ref=bullished.co), and adjusted earnings per share jumped 70% to $20.07\. The company reported Friday that its share of Sanofi's Dupixent-driven profits did the heavy lifting, and it announced an expanded Sanofi alliance with a $1.0 billion up-front payment.

## Sanofi Does The Heavy Lifting

Revenue was $5,116 million, against $3,754 million a year earlier. Sanofi collaboration revenue rose 68% to $2,724 million, as Regeneron's share of antibody profits grew to $2.575 billion from $1.456 billion on higher Dupixent sales. Sanofi records Dupixent's global sales, which rose 35% to $6.5 billion.

The Sanofi Development Balance was fully repaid at the end of the second quarter and no longer reduced Sanofi collaboration revenue starting in the third. Chief Financial Officer Christopher Fenimore called it the "first full quarter following repayment of the Development Balance."

Standard-accounting earnings per share rose 35% to $18.45, with net income of $1,949 million versus $1,460 million. Adjusted net income was $2,150 million, up from $1,287 million.

## Eye Drugs Trade Places

U.S. net sales of Eylea HD rose 62% to $699 million, while sales of the older Eylea fell 41% to $400 million on competitive pressure and patients moving to the newer drug. Combined U.S. sales of the two slipped 1% to $1,099 million.

Libtayo's global sales rose 51% to $550 million. Total net product sales were $1,805 million, up 14%. Bayer collaboration revenue, which covers Eylea sales outside the U.S., fell 23% to $267 million.

## A $1 Billion Up-Front Check

In October, Regeneron and Sanofi amended their antibody collaboration to add several next-generation, long-acting antibodies that Regeneron invented. Regeneron received $1.0 billion up front, to be recognized as collaboration revenue in the fourth quarter, and can earn up to $7.0 billion more in milestones. The companies will split costs and any future global profits equally on the new programs.

For the full year, Regeneron raised its GAAP research and development range to $6.600–$6.735 billion from $6.500–$6.635 billion. It cut GAAP SG&A to $2.730–$2.860 billion from $2.830–$2.960 billion, and lifted its GAAP gross margin outlook on product sales to about 80% from 78%–79%.

Chief Executive Leonard S. Schleifer said the company expects an FDA decision on cemdisiran in generalized myasthenia gravis next month. In the nine months through September, Regeneron repurchased $2.3 billion of stock, with $2.2 billion left under its programs.

Regeneron holds its earnings call at 8:30 a.m. ET Friday, and declared a $0.94-per-share dividend payable December 3 to holders of record November 20.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — REGENERON PHARMACEUTICALS, INC. (REGN)](https://www.sec.gov/Archives/edgar/data/0000872589/000087258926000032/regn-20261030.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit exhibit991q32026.htm — REGENERON PHARMACEUTICALS, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000872589/000087258926000032/exhibit991q32026.htm?ref=bullished.co) — SEC EDGAR
- [Regeneron Pharmaceuticals, Inc. (REGN) Stock Price, News, Quote & History - Yahoo Finance](https://ca.finance.yahoo.com/quote/REGN/?ref=bullished.co) — Yahoo Finance

### More on Regeneron Pharmaceuticals

- [Sanofi Pays Regeneron $1.0 Billion Upfront For Four Antibodies, With Up To $7.0 Billion More In Milestones](https://www.bullished.co/sanofi-pays-regeneron-1-0-billion-upfront-for-four-antibodies-with-up-to-7-0-billion-more-17b179fd/)
- [Regeneron Locks Co-Founders Into A Decade Of Performance Targets — No New Equity Until 2036](https://www.bullished.co/regeneron-locks-co-founders-into-a-decade-of-performance-targets-no-new-equity-until-2036/)

[All Regeneron Pharmaceuticals (REGN) coverage →](https://www.bullished.co/tag/regn/)